SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat) | SIGA
Description
This is an archive of https://investor.siga.com/news-releases/news-release-details/siga-receives-approval-fda-intravenous-iv-formulation-tpoxxr from Thursday 02, June 2022